Search Results - "Kher, U"

Surgical technique for socket shield procedure by Kher, U., Tunkiwala, A.

“…The socket shield procedure is a novel technique for post extraction implant placement. Several modifications of partial extraction therapy and simultaneous…”
Get full text

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study by Tabernero, J., Van Cutsem, E., Bang, Y., Fuchs, C., Wyrwicz, L., Lee, K., Kudaba, I., Garrido, M., Chung, H., Castro Salguero, H., Mansoor, W., Braghiroli, M., Goekkurt, E., Chao, J., Wainberg, Z., Kher, U., Shah, S., Kang, S., Shitara, K.

Get full text

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study by Ocio, E.M., Shah, J., Jagannath, S., Mateos, M.-V., Palumbo, A., Kher, U., Marinello, P., Miguel, J. San

Get full text

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study by Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C.S., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T.G., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.

“…In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1…”
Get full text

Combined modality therapy for primary CNS lymphoma by DeAngelis, L M, Yahalom, J, Thaler, H T, Kher, U

“…Primary CNS lymphoma (PCNSL), formerly rare, is being seen with increased frequency among apparently immunocompetent patients. Conventional treatment has…”
Get more information

Pediatric desmoid tumor: retrospective analysis of 63 cases by Faulkner, L B, Hajdu, S I, Kher, U, La Quaglia, M, Exelby, P R, Heller, G, Wollner, N

“…This study was conducted to evaluate clinical prognostic factors predictive of the probability of recurrence of desmoid tumor (DT). Sixty-three patients with…”
Get more information

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial by Murphy, Sabina A, Cannon, Christopher P, Blazing, Michael A, Giugliano, Robert P, White, Jennifer A, Lokhnygina, Yuliya, Reist, Craig, Im, KyungAh, Bohula, Erin A, Isaza, Daniel, Lopez-Sendon, Jose, Dellborg, Mikael, Kher, Uma, Tershakovec, Andrew M, Braunwald, Eugene

“…Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International…”
Get full text

The importance of clinical staging of minor salivary gland carcinoma by Spiro, R H, Thaler, H T, Hicks, W F, Kher, U A, Huvos, A H, Strong, E W

“…We reviewed a 45-year experience with 459 patients who had previously untreated minor salivary gland neoplasms, 378 (82%) of which were malignant. Data were…”
Get more information

Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study by Chung, H.C., Bang, Y.-J., Tabernero, J., Van Cutsem, E., Fuchs, C.S., Wyrwicz, L., Lee, K.-W., Kudaba, I., Garrido, M., Castro, H., Mansoor, W., Braghiroli, M.I., Goekkurt, E., Chao, J., Wainberg, Z.A., Kher, U., Shah, S., Shitara, K.

Get full text

LBA45Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma by Van Cutsem, E, Valderrama, A, Bang, Y-J, Fuchs, C, Shitara, K, Janjigian, Y Y, Qin, S, Larson, T, Shankaran, V, Stein, S, Norquist, J M, Kher, U, Shah, S, Alsina, M

“…Abstract Background KEYNOTE-062 (NCT02494583) was a randomized, active-controlled, phase III clinical trial of 1L P or P+C versus C in patients with…”
Get full text

LBA45 - Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma by Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.

“…KEYNOTE-062 (NCT02494583) was a randomized, active-controlled, phase III clinical trial of 1L P or P+C versus C in patients with HER2–negative, advanced G/GEJ…”
Get full text

Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma by Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.

Get full text

LBA-002Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study by Tabernero, J, Van Cutsem, E, Bang, Y, Fuchs, C, Wyrwicz, L, Lee, K, Kudaba, I, Garrido, M, Chung, H, Castro Salguero, H, Mansoor, W, Braghiroli, M, Goekkurt, E, Chao, J, Wainberg, Z, Kher, U, Shah, S, Kang, S, Shitara, K

Get full text

LBA44 - Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062 by Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C.S., Wyrwicz, L., Lee, K.W., Kudaba, I., Garrido, M., Cheol Chung, H., Castro, H.R., Mansoor, W., Braghiroli, M I F M, Goekkurt, E., Chao, J., Wainberg, Z.A., Kher, U., Shah, S., Kang, S.P., Tabernero, J.

“…KEYNOTE-062 (NCT02494583) was a randomized, study of 1L pembrolizumab (P) or pembro + chemo (P+C) vs chemo (C) in patients (pts) with PD-L1 combined positive…”
Get full text

LBA44Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062 by Shitara, K, Van Cutsem, E, Bang, Y-J, Fuchs, C S, Wyrwicz, L, Lee, K W, Kudaba, I, Garrido, M, Cheol Chung, H, Castro, H R, Mansoor, W, Braghiroli, M I F M, Goekkurt, E, Chao, J, Wainberg, Z A, Kher, U, Shah, S, Kang, S P, Tabernero, J

“…Abstract Background KEYNOTE-062 (NCT02494583) was a randomized, study of 1L pembrolizumab (P) or pembro + chemo (P+C) vs chemo (C) in patients (pts) with PD-L1…”
Get full text

Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062 by Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C.S., Wyrwicz, L., Lee, K.W., Kudaba, I., Garrido, M., Cheol Chung, H., Castro, H.R., Mansoor, W., Braghiroli, M I F M, Goekkurt, E., Chao, J., Wainberg, Z.A., Kher, U., Shah, S., Kang, S.P., Tabernero, J.

Get full text

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma by Mateos, M.V., Blacklock, H., Rocafiguera, A.O., Iida, S., Jagannath, S., Lonial, S., Kher, U., Farooqui, M., Marinello, P., San-Miguel, J.

Get full text

High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery by Faulkner, L B, Lindsley, K L, Kher, U, Heller, G, Black, P, Finlay, J L

“…The relative impact of age, sex, nucleated cell dose, prior chemotherapy, prior cranio-spinal irradiation (CSI) and bone marrow harvest (BMH) site on…”
Get more information

Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy by Greenspan, S L, Holland, S, Maitland-Ramsey, L, Poku, M, Freeman, A, Yuan, W, Kher, U, Gertz, B

“…The major effect of currently available antiresorptive therapy for osteoporosis is to slow or arrest bone loss. Although antiresorptive therapies demonstrate…”
Get more information

Protein wizard by Kher, U

Get full text